The Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
Abacus dx would like to update you with the latest products from Asuragen.
The FlexISH® products should give the highest flexibility to choose between a 1-day or a 2-day FISH protocol according to the laboratory workflow by adapting the hybridization time from 2 hours until over night. All products are available as 5 and 20 tests.
ZytoVision’s ZytoLight® products are designed for the identification of genetic aberrations eg. translocations, deletions, amplifications and chromosomal aneuploidies by Fluorescence in situ Hybridisation (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears and metaphase chromosome spreads.
Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.
A revolution in liquid biopsy cancer research.
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study  by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.